Dupilumab is a fully human IgG4 monoclonal antibody administered by subcutaneous injection. Following subcutaneous dosing, it is absorbed into the systemic circulation via convective lymphatic transport — the same pathway that governs the tissue distribution of all large therapeutic antibodies — and distributes broadly to tissues and organs where the IL-4 receptor alpha chain (IL-4Rα) is expressed, including skin, lung epithelium, airway smooth muscle, nasal mucosa, and esophagus. As an IgG4 isotype, dupilumab does not activate complement or drive antibody-dependent cellular cytotoxicity, a deliberate design choice to confine its pharmacology to receptor blockade rather than cell depletion.

Primary binding event. Dupilumab binds with high affinity to IL-4Rα, the shared alpha subunit common to two structurally distinct receptor complexes: the type I receptor (IL-4Rα/γc), which responds exclusively to IL-4 on hematopoietic cells including T cells, mast cells, and basophils, and the type II receptor (IL-4Rα/IL-13Rα1), which is expressed on non-hematopoietic tissues such as keratinocytes, airway epithelial cells, and smooth muscle and responds to both IL-4 and IL-13. By engaging IL-4Rα at an epitope that sterically occludes the cytokine-binding interface, dupilumab simultaneously prevents IL-4 and IL-13 from docking with either receptor complex. Structural studies place the dupilumab epitope on the extracellular domain of IL-4Rα at a site that partially overlaps with the residues contacted by both cytokines, achieving competitive antagonism without requiring the antibody to bind IL-4 or IL-13 directly.

Proximal signaling block: JAK-STAT6 pathway. Under normal conditions, cytokine binding to either IL-4R complex triggers receptor dimerization and transphosphorylation of the receptor-associated Janus kinases — JAK1 (bound constitutively to IL-4Rα) and JAK3 or TYK2 depending on the complex — leading to phosphorylation of the transcription factor STAT6 on tyrosine 641. Phosphorylated STAT6 homodimerizes, translocates to the nucleus, and drives transcription of a characteristic gene set. Dupilumab's blockade of IL-4Rα abrogates this entire cascade: receptor ligation cannot occur, JAK transactivation is prevented, and STAT6 remains unphosphorylated. The resulting suppression of STAT6 is the central mechanistic event from which all downstream pharmacology flows.

STAT6-dependent gene expression changes. In skin keratinocytes and airway epithelial cells, active STAT6 drives expression of the Th2-attracting chemokines CCL17 (TARC) and CCL18, the eosinophil chemoattractant CCL26 (eotaxin-3), and periostin, a matricellular protein that amplifies type 2 inflammation. STAT6 simultaneously suppresses expression of epidermal barrier proteins: IL-4 and IL-13 potently reduce transcription of filaggrin (FLG), loricrin (LOR), and involucrin (IVL) in keratinocytes through a STAT6-dependent mechanism that impairs corneocyte envelope formation and increases transepidermal water loss. By sustaining STAT6 suppression, dupilumab reverses this program: biopsies from treated patients show progressive normalization of the lesional transcriptome, with concurrent upregulation of FLG, LOR, claudins, and lipid metabolism genes alongside reduced IL13, CCL17, CCL18, and CCL26 expression.

Distinct and synergistic roles of IL-4 and IL-13. The rationale for blocking both cytokines simultaneously, rather than either individually, rests on their partially non-overlapping contributions to type 2 disease. IL-4 is the dominant driver of naïve CD4+ T cell polarization toward the Th2 lineage, B cell class-switching to IgE, and upregulation of the high-affinity IgE receptor (FcεRI) on mast cells and basophils. IL-13 is the principal driver of goblet cell metaplasia, mucus hypersecretion, bronchial hyperresponsiveness, airway smooth muscle proliferation, and fibroblast activation. In murine allergen challenge models, dual receptor blockade with dupilumab — but not selective neutralization of either cytokine alone — was required to fully suppress antigen-specific responses, eosinophil infiltration, and mucus production simultaneously, providing mechanistic justification for the single-antibody dual-cytokine strategy.

Parallel effects: IgE, eosinophils, and the barrier-itch-scratch cycle. Beyond transcription factor suppression, dupilumab exerts several mechanistically distinct downstream effects. IL-4-driven IgE class-switching in B cells is blocked, and circulating total and allergen-specific IgE levels fall progressively over months of treatment — though a paradoxical transient early rise in IgE can occur in some patients, likely reflecting redistribution from tissue mast cells rather than increased synthesis. Serum CCL17, CCL18, and periostin — established type 2 biomarkers — decline in parallel with clinical improvement. In the skin, reduced type 2 signaling attenuates IL-31–mediated itch transduction through sensory neurons; IL-31, whose transcription is partly STAT6-driven, directly activates pruriceptive C fibers, and dupilumab-associated reductions in IL-31 correlate with rapid improvements in itch scores preceding measurable barrier restoration. Ceramide composition in the stratum corneum — specifically the ratio of short-chain NS-ceramides to long-chain EOS-ceramides — normalizes within two to eight weeks of treatment initiation, reflecting restoration of elongase-dependent lipid biosynthesis pathways suppressed by type 2 cytokine signaling.

Translation to clinical effect. The convergence of these molecular events — sustained STAT6 suppression, barrier gene de-repression, chemokine normalization, itch signal attenuation, and lipid barrier repair — accounts for the breadth of dupilumab's clinical activity across atopic dermatitis, type 2 asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. Each of these conditions shares IL-4Rα–mediated STAT6 dysregulation as a central pathomechanism, making IL-4Rα the single upstream node whose blockade simultaneously dampens the full type 2 inflammatory signature across epithelial barrier organs.